Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 14/20 | 0.44 |
| ▸ | PRKAB2 | O43741 | 3/20 | 0.39 |
| ▸ | PRKAG1 | P54619 | 3/20 | 0.39 |
| ▸ | PRKAA2 | P54646 | 3/20 | 0.39 |
| ▸ | PRKAA1 | Q13131 | 3/20 | 0.39 |
| ▸ | PRKAG3 | Q9UGI9 | 3/20 | 0.39 |
| ▸ | PRKAG2 | Q9UGJ0 | 3/20 | 0.39 |
| ▸ | PRKAB1 | Q9Y478 | 3/20 | 0.39 |
| ▸ | CDK1 | P06493 | 1/20 | 0.37 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.37 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22049359 | 0.92 | NAMPT (0.44) | NAMPTPRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL23207543 | 0.80 | PRKAB2 (0.47) | NAMPTPRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL30176010 | 0.76 | CDK5 (0.36) | NAMPTCDK1CDK5ROCK1 | |
| SCHEMBL23194437 | 0.76 | CDK5 (0.36) | NAMPTCDK1CDK5ROCK1 | |
| SCHEMBL23194463 | 0.73 | HTR6 (0.41) | NAMPTCDK5ROCK1 | |
| SCHEMBL30176056 | 0.73 | HTR6 (0.41) | NAMPTCDK5ROCK1 | |
| SCHEMBL22049599 | 0.72 | TRPV1 (0.54) | ALDH1A1 | |
| SCHEMBL22050157 | 0.70 | CDK5 (0.46) | NAMPTCDK1CDK5 | |
| SCHEMBL23195093 | 0.70 | NPC1 (0.49) | NAMPTNPC1USP2ALDH1A1HPGD | |
| SCHEMBL23194439 | 0.69 | TRPV1 (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230002373-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-01-05 | — | — | US | disclosed |
| US-20230002373-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-01-05 | — | — | US | disclosed |
| WO-2021067791-A1 | OXALAMIDE COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | IFM DUE, INC. (US) | 2021-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230002373-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | NAMPT 2899/4885PRKAB2 158/4885PRKAG1 57/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.